Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03UEO
|
|||
| Drug Name |
Clazakizumab
|
|||
| Synonyms |
Clazakizumab; ALD518; CHEMBL2108589; BMS-945429
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN interleukin 6 (IL6) | Target Info | Inhibitor | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04348500) Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease. U.S. National Institutes of Health. | |||
| REF 2 | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452. | |||
| REF 3 | ClinicalTrials.gov (NCT04343989) A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.